In addition, a PDGFR inhibitor, dasatinib, partially reverses cancer-promoting CAFs to resting-state fibroblasts in lung adenocarcinoma (LUAC) and is a potential therapeutic strategy for LUAC [87]. The gene discussed is PDGFRB; the disease is cancer.